A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

This study aims to evaluate whether maintenance therapy with Zanubrutinib monotherapy could improve the 2-year progression free survival (PFS) of patients with mantle cell lymphoma who had remission after first-line immunochemotherapy

Trial Details

NCT ID
NCT06341556
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Mantle Cell Lymphoma Lymphoma
Interventions
  • Zanubrutinib
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥ 18 years old;
  • Histologically confirmed mantle cell lymphoma (MCL);
  • Achieved complete response (CR) or partial response (PR) through first-line sufficient treatment (including immunochemotherapy with CD20 monoclonal…
  • Signed informed consent form;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Mantle Cell Lymphoma Lymphoma Trials on Trialify →